Abstract:Microglia play diverse pathophysiological roles in Alzheimer's disease (AD), with genetic susceptibility factors skewing microglial cell function to influence AD risk. CD33 is an immunomodulatory receptor associated with AD susceptibility through a single nucleotide polymorphism that modulates mRNA splicing, skewing protein expression from a long protein isoform (CD33M) to a short isoform (CD33m). Understanding how human CD33 isoforms differentially impact microglial cell function in vivo has been challenging due to functional divergence of CD33 between mice and humans. We address this challenge by studying transgenic mice expressing either of the human CD33 isoforms crossed with the 5XFAD mouse model of amyloidosis and find that human CD33 isoforms have opposing effects on the response of microglia to amyloid-β (Aβ) deposition. Mice expressing CD33M have increased Aβ levels, more diffuse plaques, fewer disease-associated microglia, and more dystrophic neurites compared to 5XFAD control mice. Conversely, CD33m promotes plaque compaction and microglia-plaque contacts, and minimizes neuritic plaque pathology, highlighting an AD protective role for this isoform. Protective phenotypes driven by CD33m are detected at an earlier timepoint compared to the more aggressive pathology in CD33M mice that appears at a later timepoint, suggesting that CD33m has a more prominent impact on microglia cell function at earlier stages of disease progression. In addition to divergent roles in modulating phagocytosis, scRNAseq and proteomics analyses demonstrate that CD33m + microglia upregulate nestin, an intermediate filament involved in cell migration, at plaque contact sites. Overall, our work provides new functional insights into how CD33, as a top genetic susceptibility factor for AD, modulates microglial cell function.

What problem does this paper attempt to address?

This paper aims to explore how different isoforms of human CD33 related to Alzheimer's disease (AD) affect the function of microglia in vivo. Specifically, researchers generated transgenic mice expressing two major isoforms of human CD33 (CD33M and CD33m) and crossed them with 5XFAD Alzheimer's disease model mice to observe the different effects of these isoforms on microglia in response to amyloid - beta (Aβ) deposition. ### Main research questions: 1. **Functional differences of CD33 isoforms**: Study how the two isoforms, CD33M and CD33m, differently regulate the function of microglia in vivo, especially their roles in the progression of AD pathology. 2. **Effect on Aβ deposition**: Explore the effects of CD33M and CD33m on the density, morphology of Aβ deposition and the interaction between microglia and Aβ plaques. 3. **Early pathological events**: Investigate whether CD33m has a more significant effect on microglia function in the early stage of AD, thereby revealing the mechanism of early AD pathological events. ### Research methods: - **Animal models**: Use transgenic mice expressing human CD33M or CD33m to cross with 5XFAD model mice to generate the transgenic mice required for the experiment. - **Immunofluorescence staining**: Detect Aβ deposition, microglia marker Iba1, nestin, etc. through immunofluorescence staining technology. - **Microscopic analysis**: Use laser - scanning confocal microscopy for fluorescence imaging and quantitatively analyze the area, density, morphology of Aβ plaques and the contact situation between microglia and plaques. - **Proteomics analysis**: Perform proteomics analysis on the brain tissues of mice with different genotypes through mass spectrometry technology to identify differentially expressed proteins and their biological functions. ### Research significance: This study not only provides new functional insights into the role of CD33 in AD, but also provides an important basis for further understanding the pathogenesis of AD and developing potential treatment strategies. In particular, the finding that CD33m has a protective effect in the early progression of AD pathology may provide a new target for future drug development.

Alzheimer's disease associated isoforms of human CD33 distinctively modulate microglial cell responses in 5XFAD mice